Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$32.12
+0.1%		$32.88
$27.50
▼
$40.71
$1.65B0.81554,275 shs283,250 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$12.55
-2.2%		$15.31
$11.89
▼
$21.50
$1.67B2.14288,018 shs236,681 shs
uniQure N.V. stock logo
QURE
uniQure
$23.11
+1.9%		$37.41
$8.73
▼
$71.50
$1.57B1.063.76 million shs1.55 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%-7.31%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-1.56%+13.23%-0.28%-9.63%-4.41%
Mesoblast Limited stock logo
MESO
Mesoblast
+3.38%-6.96%-17.12%-20.21%-30.16%
uniQure N.V. stock logo
QURE
uniQure
-0.13%+8.20%-48.79%-42.45%-64.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$32.12
+0.1%		$32.88
$27.50
▼
$40.71
$1.65B0.81554,275 shs283,250 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$12.55
-2.2%		$15.31
$11.89
▼
$21.50
$1.67B2.14288,018 shs236,681 shs
uniQure N.V. stock logo
QURE
uniQure
$23.11
+1.9%		$37.41
$8.73
▼
$71.50
$1.57B1.063.76 million shs1.55 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%-7.31%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-1.56%+13.23%-0.28%-9.63%-4.41%
Mesoblast Limited stock logo
MESO
Mesoblast
+3.38%-6.96%-17.12%-20.21%-30.16%
uniQure N.V. stock logo
QURE
uniQure
-0.13%+8.20%-48.79%-42.45%-64.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.60
Moderate Buy$7.3354.22% Upside
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
2.58
Moderate Buy$56.3875.51% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.33
Hold$39.00210.76% Upside
uniQure N.V. stock logo
QURE
uniQure
2.76
Moderate Buy$53.25130.42% Upside

Current Analyst Ratings Breakdown

Latest IMAB, MESO, QURE, and IMCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
uniQure N.V. stock logo
QURE
uniQure
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$27.00 ➝ $48.00
10/9/2026
Mesoblast Limited stock logo
MESO
Mesoblast
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/5/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $28.00
10/2/2026
uniQure N.V. stock logo
QURE
uniQure
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$65.00 ➝ $48.00
9/30/2026
uniQure N.V. stock logo
QURE
uniQure
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$46.00 ➝ $31.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$75.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/24/2026
Mesoblast Limited stock logo
MESO
Mesoblast
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/23/2026
uniQure N.V. stock logo
QURE
uniQure
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
9/21/2026
uniQure N.V. stock logo
QURE
uniQure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/A$2.47 per shareN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$400.02M4.14N/AN/A$7.52 per share4.27
Mesoblast Limited stock logo
MESO
Mesoblast
$120.25M13.56N/AN/A$4.38 per share2.87
uniQure N.V. stock logo
QURE
uniQure
$16.10M99.57N/AN/A$3.19 per share7.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%N/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$35.51M-$0.37N/A128.48N/A-4.20%-4.54%-1.66%11/5/2026 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$57.50MN/AN/A34.86N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)

Latest IMAB, MESO, QURE, and IMCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.9152N/AN/AN/A$6.18 millionN/A
11/5/2026Q3 2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.1204N/AN/AN/A$152.86 millionN/A
8/7/2026Q2 2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.01-$0.02-$0.01-$0.02$148.57 millionN/A
7/31/2026Q4 2026
Mesoblast Limited stock logo
MESO
Mesoblast
N/A-$0.0660N/A-$0.0660N/A$34.45 million
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.82
22.82
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
0.94
4.47
4.44
Mesoblast Limited stock logo
MESO
Mesoblast
0.19
2.43
2.09
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01

Institutional Ownership

CompanyInstitutional Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
84.50%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
10.10%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
52451.50 million46.30 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
108129.88 million105.46 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable

Recent News About These Companies

uniQure (NASDAQ:QURE) Shares Gap Up - Should You Buy?
October 22 at 5:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-shares-gap-up-should-you-buy-2026-10-22/
UBS raises target for uniQure stock from USD 27 to USD 48
October 21 at 7:35 AM  |  ad-hoc-news.deA
uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25
October 21 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141369
uniQure N.V. (NASDAQ:QURE) Stock Has Average Target Price of $53.25
October 21 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-uniqure-nv-nasdaq-qure-stock-has-average-target-price-of-5325-2026-10-21/
Head-To-Head Review: ProKidney (NASDAQ:PROK) versus uniQure (NASDAQ:QURE)
October 19 at 4:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31133229
180,163 uniQure N.V. $QURE Shares Purchased by Assenagon Asset Management S.A.
October 19 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-180163-uniqure-nv-qure-shares-purchased-by-assenagon-asset-management-sa-2026-10-19/
uniQure reported AMT-130 data as uniQure stock faces FDA review
October 18, 2026  |  ad-hoc-news.deA
uniQure: The Market Graded The Wrong Exam
October 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954484-uniqure-market-graded-the-wrong-exam?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments
October 13, 2026  |  newsfilecorp.comN
Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-uniqure-qure-down-5-130921750.html
Two Seas Capital LP Purchases 1,324,022 Shares of uniQure N.V. $QURE
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-seas-capital-lp-purchases-1324022-shares-of-uniqure-nv-qure-2026-10-06/
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261006814990/en/uniqure-n.v.-qure-investors-contact-kirby-mcinerney-llp-about-the-firm%e2%80%99s-securities-investigation-following-37.3-share-drop/
uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-stock-price-down-55-following-analyst-downgrade-2026-10-06/
Barclays Downgrades uniQure to Equal Weight From Overweight
October 5, 2026  |  marketscreener.comM
Barclays downgrades uniQure NV to equal-weight from overweight
October 5, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/barclays-downgrades-uniqure-nv-to-equal-weight-from-overweight/ar-AA2dBqF9
uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-shares-gap-down-on-analyst-downgrade-2026-10-05/
uniQure (NASDAQ:QURE) Cut to Equal Weight at Barclays
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-uniqure-nasdaq-qure-cut-to-equal-weight-at-barclays-2026-10-05/
Barclays Sticks to Their Buy Rating for uniQure (QURE)
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/QURE/pressreleases/4898440/barclays-sticks-to-their-buy-rating-for-uniqure-qure/
RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk
October 2, 2026  |  marketscreener.comM
10 Stocks With Massive Short Squeeze Potential
October 1, 2026  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/analysis/2026/10/01/10-stocks-with-massive-short-squeeze-potential
uniQure (QURE) Stock Plunges 48% After Huntington’s Drug Data Miss
October 1, 2026  |  coincentral.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

I-Mab stock logo

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$32.12 +0.03 (+0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$32.03 -0.09 (-0.26%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$12.55 -0.28 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$12.62 +0.06 (+0.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

uniQure stock logo

uniQure NASDAQ:QURE

$23.11 +0.42 (+1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$22.99 -0.12 (-0.51%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas